Theodore R. Schroeder - 31 Mar 2022 Form 4 Insider Report for Nabriva Therapeutics plc

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
N/A
Transactions as of
31 Mar 2022
Net transactions value
-$43.68
Form type
4
Filing time
04 Apr 2022, 18:27:21 UTC
Previous filing
08 Mar 2022
Next filing
08 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRV Ordinary Shares Tax liability $43.68 -104 -0.03% $0.4200 313,856 31 Mar 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.